BiomX Business Summary

BiomX Inc. (PHGE) is a clinical-stage biotechnology company that generates revenue primarily through non-dilutive grant funding from entities like the U.S. Defense Health Agency and the Israel Innovation Authority, alongside strategic collaboration and licensing agreements with pharmaceutical partners such as Boehringer Ingelheim and Janssen. The company’s primary business segments are centered on its proprietary BOLT (BacteriOphage Lead to Treatment) platform, which develops both natural and engineered phage cocktails to target pathogenic bacteria. Following the 2024 acquisition of Adaptive Phage Therapeutics, the company has prioritized its clinical pipeline on BX011 for diabetic foot infections (DFI) and BX211 for diabetic foot osteomyelitis (DFO), while recently discontinuing its cystic fibrosis program (BX004) in late 2025. BiomX competes directly with Armata Pharmaceuticals, Locus Biosciences, and PHAXIAM Therapeutics, positioning itself as a consolidated leader in the phage therapy space with one of the most advanced clinical-stage pipelines for antibiotic-resistant infections. The company was co-founded in 2015 by Eran Ofir, Raya Sorkin, and scientific founder Dr. Timothy K. Lu, with a foundation built on research from the Weizmann Institute of Science and MIT. As of March 2026, the leadership team has undergone a significant overhaul, with Michael Oster appointed as Chief Executive Officer in March 2026, bringing extensive experience in corporate strategy and M&A from roles at Alon USA Energy and Saffron Tech. He is supported by Chief Financial Officer David Rokach, an investment management veteran appointed in February 2026. Notable institutional backing includes Deerfield Management, the AMR Action Fund, and the Cystic Fibrosis Foundation, with Pyu Pyu Capital LLC recently disclosing a 19.99% stake. The board of directors includes newly appointed independent members such as Reuven Yeganeh, Amir Shalom, and Guy Arieli, reflecting a strategic shift toward financial and operational restructuring.